RE:Response to PipelinesAs the management teams in the vast majority of failed BioTechs discovered, good Science alone is not enough. It also takes a reliable cash source, competent management to sell the science and a timelines that does not chisel a revenue accomplishment as a p.s. on investors tombstones.